Literature DB >> 17009061

Biological therapies: concepts and challenges.

Markus Müller1.   

Abstract

Mesh：

Year:  2006        PMID： 17009061     DOI： 10.1007/s00508-006-0670-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  21 in total

1.  Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade.

Authors:  Julia Kleinert; Matthias Lorenz; Wolfgang Köstler; Walter Hörl; Gere Sunder-Plassmann; Afschin Soleiman
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

Review 2.  Why drugs fail--a study on side effects in new chemical entities.

Authors:  D Schuster; C Laggner; T Langer
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

3.  Models of Phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events.

Authors:  Allan Saul
Journal:  Vaccine       Date:  2005-04-27       Impact factor: 3.641

Review 4.  Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Strategies for designing clinical trials for oligonucleotide therapeutics.

Authors:  Volker Wacheck
Journal:  Drug Discov Today       Date:  2004-11-01       Impact factor: 7.851

6.  What went wrong in the natalizumab trials?

Authors:  Annette Langer-Gould; Lawrence Steinman
Journal:  Lancet       Date:  2006-03-04       Impact factor: 79.321

7.  Learning from the TGN1412 trial.

Authors:  Michael Goodyear
Journal:  BMJ       Date:  2006-03-22

8.  Biotechnology's metamorphosis into a drug discovery industry.

Authors:  J Drews
Journal:  Nat Biotechnol       Date:  1998-05       Impact factor: 54.908

9.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

Review 10.  Alzheimer's amyloid immunotherapy: quo vadis?

Authors:  Sam Gandy; Frank L Heppner
Journal:  Lancet Neurol       Date:  2005-08       Impact factor: 44.182
View more
  1 in total

1.  [Generics in Austria 2003-2008: an update].

Authors:  Markus Müller
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.